Eloralintide is an investigational selective amylin receptor agonist being studied for obesity and cardiometabolic conditions. It acts on amylin-related signaling pathways involved in appetite regulation and feelings of fullness. Clinical research is evaluating its potential effects on body-weight management and metabolic health.